Alcon Acquired by Novartis
On December 15, 2010, Novartis (NYSE: NVS) agreed to acquire the remaining shares of Alcon, Inc. (NYSE: ACL) it doesn't currently own for $168 per share.
The merger consideration will be comprised of a combination of Novartis shares and, if necessary, a cash contingent value amount to result in a total value of $168 per share.
Upon completion of the merger, Alcon will become the second largest division within Novartis. CIBA VISION and select Novartis ophthalmic medicines will be integrated into Alcon, forming an organization with more than $8.7 billion in sales covering over 70 percent of the eye care segment.
The merger consideration will be comprised of a combination of Novartis shares and, if necessary, a cash contingent value amount to result in a total value of $168 per share.
Upon completion of the merger, Alcon will become the second largest division within Novartis. CIBA VISION and select Novartis ophthalmic medicines will be integrated into Alcon, forming an organization with more than $8.7 billion in sales covering over 70 percent of the eye care segment.
Valitor Appoints Biotech and Ophthalmic Industry Veteran Gregory D. Kunst as Chief Executive Officer
View Older Stories
-
PolyActiva Expands Executive Team to Drive Transformational Growth and Advance Late-Stage Clinical Development in the U.S.
-
Glenmark Therapeutics Inc., USA launches Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC)
-
Tavo Biotherapeutics Announces Appointment of Seasoned Executives to Key Posts
-
Glenmark receives ANDA approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC)
-
Bernstein SocGen Group Reinstates Alcon Inc. (ALC) at Outperform
-
Bernstein SocGen Group Reinstates Alcon Inc. (ALC:SW) (ALC) at Outperform
-
Pharma Executive and Gene Therapy Access Expert, Ramesh Arjunji, PhD, Joins Nanoscope as Executive Vice President, Value and Access
-
Alcon Inc. (ALC) PT Raised to $108 at Needham, Added to Conviction List, Top Pick 2025
-
Tempest Therapeutics (TPST) Appoints Troy M. Wagner as VP of Quality Assurance
-
Tempest Announces the Appointment of Troy M. Wagner as Vice President of Quality Assurance
-
Glenmark Therapeutics Inc., USA launches Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1% (OTC)
-
4DMT Advances Leadership in Large Market Ophthalmology with Senior Management Hires and Formation of Ophthalmology Advisory Board
-
Stuart Therapeutics, Inc. Announces Key Addition to its Executive Team
-
Hainan Free Trade Port deepens cooperation with Switzerland
-
Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board
-
Imre Continues its Brand AOR Evolution with Industry Veteran Christian Bauman as Chief Creative Officer
-
Cagent Vascular appoints Chairman Brian Walsh to expanded role as Chief Executive Officer
-
Ocular Therapeutix (OCUL) Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO
-
Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO
-
Precision Neuroscience Names Verily Co-Founder Brian Otis as Chief Technology Officer
-
PulseSight Therapeutics Launches to Advance Non-viral Gene Therapies with Disruptive Minimally-Invasive Delivery Technology for Severe Retinal Diseases
-
Ocular Therapeutix (OCUL) Announces Board and Leadership Updates
-
Ocular Therapeutix™ Announces Board of Directors and Leadership Updates
-
Opthea (OPT) Announces Management Changes
-
Opthea Strengthens Team with Key Clinical and Regulatory Hires
-
Harrow Announces New Appointments to its Board of Directors
-
biote (BTMD) Appoints Robert Peterson as CFO
-
Biote Names Robert Peterson as Chief Financial Officer
-
AccentCare Announces Appointment of Saurabh Gupta as Chief Financial Officer
-
Opthea Appoints U.S.-Based Leadership with Fred Guerard as CEO and Peter Lang as CFO
-
Nanoscope Therapeutics Strengthens Research and Development Leadership with Appointment of Najam Sharif, PhD, DSc.
-
CORRECTING and REPLACING RepeatMD Welcomes Aesthetics Industry Veteran Aaron Green as New Vice President of Business Development
-
RepeatMD Welcomes Aaron Green, former Galderma Executive, as New Vice President of Business Development
-
Aitia Appoints Drug R&D Executive Jean-Michel Gries as President & Chief Operating Officer
-
Oculis Holding (OCS) Appoints Rebecca Weil as Chief Commercial Officer
-
Oculis Expands its Executive Leadership Team and Appoints Rebecca Weil, Ph.D. as Chief Commercial Officer as it Enters Pre-Commercial Phase
-
Verona Pharma plc (VRNA) Appoints Christina Ackermann to its Board
-
Christina Ackermann Joins Verona Pharma as Non-Executive Director
-
The Galien Foundation Announces 2023 Prix Galien USA Nominees for "Best Digital Health Solution," "Best Medical Technology," "Incubators, Accelerators and Equity," and &q
-
Vertex Ventures HC Announces $200 Million Fund III to Drive Innovation in Healthcare
-
Oculis to Host an R&D Retina Day to Showcase Clinical Programs Targeting Diabetic Macular Edema and Other Retina Diseases on Tuesday, July 11, 2023
-
Oculis (OCS) Opens New Offices in the US
-
Oculis Opens New Offices in the US and Expands its US Team by Appointing Dr. Fang Li as Senior Vice President, Regulatory Affairs
-
Oculis Opens New Offices in the US and Expands its US Team by Appointing Dr. Fang Li as Senior Vice President, Regulatory Affairs
-
GL CHEMTEC Announces Formation of Scientific Advisory Board
-
A LIFESTYLE EPIDEMIC: OCULAR SURFACE DISEASE
-
Spiral Therapeutics Acquires Otonomy Assets to Boost Inner Ear Disorders Pipeline and Appoints Industry Leaders to Board
-
Alcon to Debut TOTAL30 for Astigmatism, Dry Eye and Ocular Health Innovations at SECO 2023
-
HiveWatch Adds Jamie Howard to Board of Directors, Formalizes Board of Advisors
-
Rapidly Growing Patent Law Firm in Spokane Adds Pharmaceutical Division with New Dallas-Based Partner
